The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates High-fat Induced Cognitive Decline in Tauopathy Model Mice
Vascular risk factors, such as type 2 diabetes mellitus (T2DM), are associated with the increased risk of Alzheimer’s disease. One of the common T2DM medications, dipeptidyl peptidase (DPP)-4 inhibitors, have a minimum risk for hypoglycemia and have recently been suggested to ameliorate &a...
Main Authors: | Yuriko Nakaoku, Satoshi Saito, Yumi Yamamoto, Takakuni Maki, Ryosuke Takahashi, Masafumi Ihara |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-05-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/20/10/2539 |
Similar Items
-
Dipeptidyl peptidase IV and its implication in cancer
by: Yarini M Arrebola, et al. -
Dipeptidyl Peptidase-4 Inhibitors for the Potential Treatment of Brain Disorders; A Mini-Review With Special Focus on Linagliptin and Stroke
by: Vladimer Darsalia, et al.
Published: (2019-05-01) -
The persistent inhibitory properties of saxagliptin on renal dipeptidyl peptidase-4: Studies with HK-2 cells in vitro and normal rats in vivo
by: Masako Uchii, et al.
Published: (2017-11-01) -
Association between Serum Dipeptidyl Peptidase-4 Concentration and Obesity-related Factors in Health Screen Examinees
by: Ji Yeon Lee, et al.
Published: (2017-09-01) -
Dipeptidyl peptidase-4 levels are increased and partially related to body fat distribution in patients with familial partial lipodystrophy type 2
by: Cynthia Melissa Valerio, et al.
Published: (2017-04-01)